Display options
Cite
Najar M, Krayem M, Meuleman N, et al. Mesenchymal Stromal Cells and Toll-Like Receptor Priming: A Critical Review. Immune Netw. 2017;17(2):89-102doi: 10.4110/in.2017.17.2.89.
Najar, M., Krayem, M., Meuleman, N., Bron, D., & Lagneaux, L. (2017). Mesenchymal Stromal Cells and Toll-Like Receptor Priming: A Critical Review. Immune network, 17(2), 89-102. https://doi.org/10.4110/in.2017.17.2.89
Najar, Mehdi, et al. "Mesenchymal Stromal Cells and Toll-Like Receptor Priming: A Critical Review." Immune network vol. 17,2 (2017): 89-102. doi: https://doi.org/10.4110/in.2017.17.2.89
Najar M, Krayem M, Meuleman N, Bron D, Lagneaux L. Mesenchymal Stromal Cells and Toll-Like Receptor Priming: A Critical Review. Immune Netw. 2017 Apr;17(2):89-102. doi: 10.4110/in.2017.17.2.89. Epub 2017 Apr 20. PMID: 28458620; PMCID: PMC5407987.
Copy Download .nbib Format: NLM
Share it on

Immune Netw. 2017 Apr;17(2):89-102. doi: 10.4110/in.2017.17.2.89. Epub 2017 Apr 20.

Mesenchymal Stromal Cells and Toll-Like Receptor Priming: A Critical Review.

Immune network

Mehdi Najar, Mohammad Krayem, Nathalie Meuleman, Dominique Bron, Laurence Lagneaux

Affiliations

  1. Laboratory of Clinical Cell Therapy, Institut Jules Bordet, Université Libre de Bruxelles (ULB), Campus Erasme, Belgium.
  2. Laboratory of Oncology and Experimental Surgery, Institut Jules Bordet, Université Libre de Bruxelles, Brussels 1000, Belgium.

PMID: 28458620 PMCID: PMC5407987 DOI: 10.4110/in.2017.17.2.89

Abstract

Mesenchymal Stromal Cells (MSCs) are potential cellular candidates for several immunotherapy purposes. Their multilineage potential and immunomodulatory properties make them interesting tools for the treatment of various immunological diseases. However, depending on the local microenvironment, diverse biological functions of MSCs can be modulated. Indeed, during infections such as obtained following TLR-agonist engagement (called as TLR priming), the phenotype, multilineage potential, hematopoietic support and immunomodulatory capacity of MSCs can present critical changes, which could further affect their therapeutic potential. Thus, for appropriate clinical application of MSCs, it is important to well know and understand these effects in particular during infectious episodes and to find the suitable experimental settings to study that. Pre-stimulation of MSCs with a specific TLR ligand may serve as an effective priming step to modulate one of its function to achieve a desired therapeutic issue.

Keywords: Hematopoietic support; Immunomodulation; MSCs; Multilineage potential; Phenotype; Priming; TLR

Conflict of interest statement

CONFLICTS OF INTEREST: The authors declare no potential conflicts of interest.

References

  1. Tissue Eng Part A. 2012 Jul;18(13-14):1410-8 - PubMed
  2. Artif Cells Nanomed Biotechnol. 2016 May;44(3):749-57 - PubMed
  3. Blood. 2008 Feb 1;111(3):1437-47 - PubMed
  4. Ciba Found Symp. 1988;136:42-60 - PubMed
  5. Trends Immunol. 2007 May;28(5):219-26 - PubMed
  6. Stem Cells Dev. 2011 Apr;20(4):695-708 - PubMed
  7. Cell Commun Signal. 2011 May 14;9:12 - PubMed
  8. Nat Immunol. 2010 May;11(5):373-84 - PubMed
  9. Cell Immunol. 2011;270(2):207-16 - PubMed
  10. Annu Rev Immunol. 2013;31:285-316 - PubMed
  11. Front Immunol. 2013 Jul 25;4:211 - PubMed
  12. PLoS One. 2010 Apr 26;5(4):e10088 - PubMed
  13. Am J Transl Res. 2016 Jun 15;8(6):2490-7 - PubMed
  14. Annu Rev Immunol. 2002;20:197-216 - PubMed
  15. Nat Rev Immunol. 2001 Nov;1(2):135-45 - PubMed
  16. World J Gastroenterol. 2007 Nov 14;13(42):5577-80 - PubMed
  17. J Cell Biochem. 2006 Aug 1;98(5):1076-84 - PubMed
  18. Stem Cell Rev. 2014 Jun;10(3):376-88 - PubMed
  19. Stem Cells. 2007 Jun;25(6):1384-92 - PubMed
  20. Nat Rev Immunol. 2008 Jan;8(1):81-6 - PubMed
  21. Cell. 2010 Mar 19;140(6):805-20 - PubMed
  22. Cell Immunol. 2011;271(1):147-56 - PubMed
  23. Int J Mol Med. 2015 Apr;35(4):1003-10 - PubMed
  24. Sci Rep. 2014 Apr 02;4:4565 - PubMed
  25. FASEB J. 2014 Sep;28(9):3856-66 - PubMed
  26. Curr Pharm Des. 2006;12(32):4215-28 - PubMed
  27. PLoS One. 2012;7(6):e39592 - PubMed
  28. Tissue Eng Part B Rev. 2014 Oct;20(5):523-44 - PubMed
  29. Dev Growth Differ. 2014 Apr;56(3):233-44 - PubMed
  30. Nature. 2010 Aug 12;466(7308):829-34 - PubMed
  31. Cytotherapy. 2005;7(5):393-5 - PubMed
  32. Immunobiology. 2017 Feb;222(2):394-398 - PubMed
  33. Scand J Immunol. 2010 Apr;71(4):267-74 - PubMed
  34. Cells Tissues Organs. 2003;174(3):101-9 - PubMed
  35. Nature. 2007 Oct 18;449(7164):819-26 - PubMed
  36. Arch Med Res. 2015 Nov;46(8):589-96 - PubMed
  37. Cell Stem Cell. 2011 Jul 8;9(1):11-5 - PubMed
  38. Biochem Biophys Res Commun. 2014 May 30;448(2):212-7 - PubMed
  39. Stem Cells. 2017 Jan;35(1):265-275 - PubMed
  40. Stem Cells. 2014 Jan;32(1):290-300 - PubMed
  41. Cytotherapy. 2016 May;18(5):630-41 - PubMed
  42. Curr Opin Immunol. 2008 Aug;20(4):420-5 - PubMed
  43. Mediators Inflamm. 2010;2010:865601 - PubMed
  44. Stem Cells. 2009 Apr;27(4):909-19 - PubMed
  45. Stem Cells. 2008 Jan;26(1):279-89 - PubMed
  46. J Cell Physiol. 2010 Apr;223(1):168-77 - PubMed
  47. Cytotherapy. 2006;8(4):315-7 - PubMed
  48. Immunity. 2009 Dec 18;31(6):873-84 - PubMed
  49. Int Rev Immunol. 2011 Feb;30(1):16-34 - PubMed
  50. PLoS One. 2014 Jul 08;9(7):e101558 - PubMed
  51. J Cell Physiol. 2008 Nov;217(2):296-300 - PubMed
  52. Biochem Biophys Res Commun. 2015 Aug 21;464(2):541-7 - PubMed
  53. Ann Hematol. 2016 Jan;95(2):173-8 - PubMed
  54. Hum Immunol. 2016 Jun;77(6):476-82 - PubMed
  55. Cytokine. 2015 Jun;73(2):225-35 - PubMed
  56. Mucosal Immunol. 2017 May;10 (3):727-742 - PubMed
  57. Mol Med Rep. 2016 Jun;13(6):4969-80 - PubMed
  58. Stem Cells. 2008 Jan;26(1):99-107 - PubMed
  59. Exp Mol Med. 2007 Aug 31;39(4):421-38 - PubMed
  60. Blood. 2007 Feb 15;109(4):1422-32 - PubMed
  61. Immunity. 2011 Apr 22;34(4):590-601 - PubMed
  62. J Virol. 2009 Oct;83(20):10548-56 - PubMed
  63. Immunotherapy. 2016 Jul;8(8):839-42 - PubMed
  64. Biochem J. 2009 Apr 28;420(1):1-16 - PubMed
  65. Cytotherapy. 2009;11(5):503-15 - PubMed
  66. J Endotoxin Res. 2005;11(2):124-8 - PubMed
  67. Int Immunopharmacol. 2013 Apr;15(4):693-702 - PubMed
  68. Am J Physiol Heart Circ Physiol. 2005 Sep;289(3):H1069-76 - PubMed
  69. Blood Rev. 2003 Dec;17(4):187-94 - PubMed
  70. Med Oral Patol Oral Cir Bucal. 2016 Jan 01;21(1):e30-8 - PubMed
  71. Stem Cells. 2014 Feb;32(2):521-33 - PubMed
  72. PLoS One. 2010 Oct 22;5(10):e15369 - PubMed
  73. Stem Cells Dev. 2007 Oct;16(5):797-810 - PubMed
  74. Tissue Eng Part A. 2009 Jul;15(7):1579-89 - PubMed
  75. Trends Immunol. 2014 Jan;35(1):32-7 - PubMed
  76. Clin Exp Immunol. 2007 Feb;147(2):199-207 - PubMed
  77. Cell Microbiol. 2016 Mar;18(3):424-36 - PubMed
  78. Stem Cells Int. 2014;2014:917168 - PubMed
  79. J Immunol. 2010 May 1;184(9):5094-103 - PubMed
  80. Nat Immunol. 2004 Oct;5(10):987-95 - PubMed
  81. BMC Cell Biol. 2008 Sep 18;9:52 - PubMed
  82. Cell Stem Cell. 2013 Oct 3;13(4):392-402 - PubMed
  83. Science. 1999 Apr 2;284(5411):143-7 - PubMed
  84. Stem Cell Rev. 2015 Dec;11(6):826-40 - PubMed
  85. Stem Cells. 2006 Dec;24(12):2744-52 - PubMed
  86. Exp Cell Res. 2012 Feb 1;318(3):196-206 - PubMed
  87. Cell. 2007 Sep 21;130(6):1071-82 - PubMed
  88. Stem Cells. 2011 Jun;29(6):1001-11 - PubMed
  89. Cytotherapy. 2016 Feb;18(2):160-71 - PubMed
  90. Eur J Immunol. 2013 Oct;43(10):2741-9 - PubMed
  91. J Immunol. 2009 Jun 15;182(12):7963-73 - PubMed
  92. Exp Mol Med. 2013 Nov 15;45:e54 - PubMed
  93. Hum Immunol. 2010 Mar;71(3):235-44 - PubMed
  94. J Immunother. 2016 Feb-Mar;39(2):45-59 - PubMed
  95. J Cell Mol Med. 2009 Sep;13(9B):3415-26 - PubMed
  96. PLoS One. 2016 Mar 01;11(3):e0149876 - PubMed
  97. Placenta. 2016 Aug;44:69-79 - PubMed
  98. Blood. 2017 Jan 12;129(2):171-176 - PubMed

Publication Types